Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.